10-K: SANUWAVE Health Reports Strong Revenue Growth in 2024, But Losses Persist Due to Derivative Valuations

SANUWAVE Health achieved a 60% increase in revenue for 2024, driven by UltraMIST sales, but net losses continued due to changes in derivative valuations and debt related costs.

Summary

• SANUWAVE Health, Inc., a medical device company focused on regenerative medicine, reported its financial results for the year ended December 31, 2024.
• The company's total revenues increased by 60% to $32.6 million in 2024, compared to $20.4 million in 2023, with UltraMIST systems and consumables accounting for approximately 98% of the revenue.
• Gross margins improved to 75% in 2024 from 70% in 2023, driven by increased pricing on UltraMIST systems and applicators.
• Operating income increased significantly to $5.4 million in 2024, compared to an operating loss of $0.5 million in 2023.
• However, the company still reported a net loss of $31.4 million, or $7.03 per share, for 2024, compared to a net loss of $25.8 million, or $12.19 per share, in 2023, primarily due to a non-cash change in the fair value of derivatives.
• The company had over 1,000 UltraMIST systems in the field as of December 31, 2024.
• The company plans to focus on building a direct sales force and distribution network to market the UltraMIST product in the United States and to assess potential expansion abroad.
• The company identified material weaknesses in its internal control over financial reporting and determined that its disclosure controls and procedures were ineffective as of December 31, 2024.
• Management plans to obtain additional capital in 2025 through the issuance of common or preferred stock, securities convertible into common stock, or secured or unsecured debt.
• The company's Senior Secured Note becomes due in September 2025, raising concerns about its ability to continue as a going concern.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While revenue growth and improved operating income are positive, the net loss, material weaknesses in internal controls, and going concern uncertainty temper the overall sentiment.

Positives

• Significant revenue growth of 60% in 2024, driven by UltraMIST sales.
• Improved gross margins, increasing to 75% in 2024.
• Substantial increase in operating income, reaching $5.4 million in 2024.
• Over 1,000 UltraMIST systems deployed in the field as of December 31, 2024.
• The company is focusing on expanding its direct sales force and distribution network for UltraMIST.

Negatives

• Net loss of $31.4 million in 2024, primarily due to non-cash changes in the fair value of derivatives.
• Material weaknesses identified in internal control over financial reporting.
• Ineffective disclosure controls and procedures as of December 31, 2024.
• Senior Secured Note due in September 2025 raises concerns about the company's ability to continue as a going concern.

Risks

• Recurring losses from operations and dependence on future financing raise substantial doubt about the company's ability to continue as a going concern.
• Failure to remediate material weaknesses in internal control over financial reporting could lead to material misstatements in financial statements.
• Intense competition in the medical device industry and rapid technological changes could reduce commercial opportunities.
• Dependence on single suppliers for product component materials could disrupt manufacturing.
• Product liability claims could result in financial loss.
• Cybersecurity breaches and data leakage could negatively impact operations.
• Failure to obtain adequate reimbursement for approved products by third-party payors could limit market viability.
• Uncertainty surrounding healthcare law in the United States may have a material adverse effect on the company.
• Failure to comply with the Federal Anti-Kickback Statute and False Claims Act could result in penalties and exclusion from Medicare and Medicaid programs.
• Failure to comply with HIPAA and state-specific privacy laws may increase operational costs.

Future Outlook

The company plans to focus on building a direct sales force and distribution network to market the UltraMIST product in the United States and to assess potential expansion abroad. Management plans to obtain additional capital in 2025 through the issuance of common or preferred stock, securities convertible into common stock, or secured or unsecured debt.

Management Comments

• We believe these improvements set the stage for additional growth as we head into 2025.

Industry Context

The wound care market exceeds $45 billion per year in the United States. The Centers for Medicare and Medicaid Services (the 'CMS') have increasingly classified regenerative technology as medically necessary. With an aging population and high incidence of obesity, diabetes, cancers, and autoimmune disorders, the Company believes this market is likely to continue to expand.

Comparison to Industry Standards

• The leading medical device serving this market is the Vacuum Assisted Closure (V.A.C.) System marketed by Kinetic Concepts Inc. (now owned by 3M).
• There are also several companies that market extracorporeal shockwave device products targeting lithotripsy and orthopedic markets, including Dornier MedTech, Storz Medical AG, Electro Medical Systems (EMS) S.A., SoftWave Tissue Regeneration Technologies, and CellSonic Medical, which could ultimately pursue the wound care market.
• Regarding the companies that use low frequency ultrasound that creates a pressure wave producing micro-strains due to mechanical forces that deform cell membrane and therefore promote healing, there are technologies developed by Arobella Medical LLC, NanoVibronix, Chattanooga, and EDAP TMS to manage wound care.

Corporate Governance

Legal Proceedings

• In the ordinary course of business, the Company from time to time becomes involved in various legal proceedings involving a variety of matters.

Related Party Transactions

• In June 2024 the Company entered into a $0.5 million promissory note with a related party.
• In August 2022 and November 2022, the Company entered into Purchase Agreements for the sale of Notes and Common Stock Purchase Warrants in an aggregate principal amount of $16.2 million in August and $4.0 million in November to related parties.
• In May 2023 and December 2023, the Company entered into Purchase Agreements for the sale of Notes and Common Stock Purchase Warrants in an aggregate principal amount of $1.2 million and $1.8 million, respectively to related parties.
• In July 2023, the Company issued Asset-Backed Secured Promissory Notes ("ABS Promissory Notes") in the aggregate principal amount of $4.6 million at an original issue discount of 33.33% to related parties.

Stakeholder Impact

• Shareholders face potential dilution from future capital raises.
• Employees may be affected by cost-cutting measures if the company's financial situation does not improve.
• Customers may be impacted by the company's ability to invest in product development and support.
• Creditors face increased risk due to the company's going concern uncertainty.

Next Steps

• Obtain additional capital in 2025.
• Refinance the Senior Secured Note due in September 2025.
• Continue to implement and enhance appropriate internal controls.
• Collaborate with an external vendor to enhance IT general controls over the enterprise resource planning system.

Key Dates

Keywords

SANUWAVE Health, UltraMIST, revenue growth, financial results, medical device, wound care, internal control, going concern, derivative valuation, Senior Secured Note